| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF7 |
| Uniprot No | P32970 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 39-193aa |
| 氨基酸序列 | QRFAQAQQQL PLESLGWDVA ELQLNHTGPQ QDPRLYWQGG PALGRSFLHG PELDKGQLRI HRDGIYMVHI QVTLAICSST TASRHHPTTL AVGICSPASR SISLLRLSFH QGCTIASQRL TPLARGDTLC TNLTGTLLPS RNTDETFFGV QWVRP |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF7(CD70)重组蛋白研究的3篇示例文献(虚构示例，供参考)：
1. **标题**: "High-yield production of soluble recombinant TNFSF7 in mammalian cells and its functional characterization"
**作者**: Zhang L, et al.
**期刊**: *Protein Expression and Purification*
**摘要**: 研究通过HEK293细胞表达系统高效生产可溶性TNFSF7重组蛋白，优化了分泌表达条件，并通过亲和层析纯化获得高纯度蛋白。功能实验证实其可激活CD27信号通路，促进T细胞增殖。
2. **标题**: "Structural basis of CD70-TNFSF7 recognition by CD27 revealed by X-ray crystallography"
**作者**: Wang Y, et al.
**期刊**: *Nature Communications*
**摘要**: 解析了TNFSF7重组蛋白与其受体CD27的复合物晶体结构，揭示了二者结合的关键氨基酸残基，为设计靶向CD27-CD70通路的免疫治疗药物提供了结构基础。
3. **标题**: "Recombinant TNFSF7 enhances antitumor immunity in murine lymphoma models"
**作者**: Kim HJ, et al.
**期刊**: *Cancer Immunology Research*
**摘要**: 利用大肠杆菌表达系统制备重组TNFSF7蛋白，通过小鼠淋巴瘤模型验证其与PD-1抑制剂联用的协同抗肿瘤效果，证明其通过激活效应T细胞抑制肿瘤生长。
4. **标题**: "TNFSF7-mediated costimulation in autoimmune disease: Insights from recombinant protein blockade"
**作者**: Müller R, et al.
**期刊**: *Journal of Autoimmunity*
**摘要**: 开发了TNFSF7-Fc融合蛋白，在类风湿性关节炎模型中验证其通过阻断CD27-CD70相互作用抑制过度T细胞活化，提出其作为自身免疫疾病治疗策略的潜力。
---
注：以上文献为示例性内容，实际研究中建议通过PubMed或Web of Science检索真实文献(关键词：TNFSF7/CD70 recombinant protein)。
TNFSF7. also known as CD70. is a member of the tumor necrosis factor (TNF) superfamily and plays a critical role in regulating immune responses. It is a type II transmembrane protein primarily expressed on activated T cells, B cells, and dendritic cells. The soluble form of TNFSF7. generated through proteolytic cleavage or alternative splicing, interacts with its receptor CD27. a TNF receptor family protein expressed on lymphocytes. This interaction triggers co-stimulatory signals that enhance T-cell proliferation, B-cell differentiation, and antibody production, thereby bridging innate and adaptive immunity.
Recombinant TNFSF7 protein is produced using expression systems like mammalian cells (e.g., CHO or HEK293) to ensure proper post-translational modifications and structural fidelity. Structurally, it contains a conserved TNF homology domain critical for trimer formation and receptor binding. Researchers utilize this recombinant protein to study CD70-CD27 signaling pathways, which are implicated in autoimmune diseases, chronic inflammation, and cancer. For instance, CD70 overexpression in certain tumors promotes immune evasion, making it a potential therapeutic target. Conversely, dysregulated CD70-CD27 signaling is linked to autoimmune disorders like lupus.
In therapeutic development, recombinant TNFSF7 or its antagonists (e.g., monoclonal antibodies) are being explored to modulate immune responses. Blocking CD70-CD27 axis has shown promise in preclinical cancer models to suppress tumor growth, while agonist strategies aim to boost antitumor immunity. Additionally, it serves as a tool in vaccine research to enhance antigen-specific immune activation. The production and quality control of recombinant TNFSF7 emphasize bioactivity, low endotoxin levels, and purity to ensure experimental reproducibility and therapeutic safety.
×
